Question 1

FDA Status and Indications

Accepted Answer

This page is provided for educational purposes, summarizing findings from published research and ongoing clinical studies. The information here does not constitute medical advice or a guarantee of results. Individual outcomes vary significantly.

Question 2

Understanding FDA Status

Accepted Answer

The BTL ExoMind™ TMS device is FDA-cleared specifically for the treatment of Major Depressive Disorder (MDD). All other conditions listed below are considered investigational or "off-label" uses of this technology.

Question 3

What is "Off-Label" Use?

Accepted Answer

"Off-label" refers to the professional use of an FDA-approved treatment for a condition other than the one for which it was officially cleared. This practice is based on available scientific evidence and clinical judgment. However, off-label use involves inherent uncertainties, and benefit is not guaranteed for all patients.

Question 4

FDA-Cleared Indication

Accepted Answer

Major Depressive Disorder (MDD)

Question 5

Investigational/Off-Label Indication

Accepted Answer

Indicates an off-label/investigational use.

Question 6

Our Educational Approach

Accepted Answer

We prioritize factual, evidence-based information. Our materials:
Focus on what research suggests and where studies are ongoing.
Use conditional phrasing (e.g., "may help" or "potential") rather than absolute claims.
Provide references to clinical evidence Medical Disclaimer and Terms of Use.

Question 7

Safety & Informed Consent

Accepted Answer

The Informed-Consent Process
Every patient receives a written consent form that explicitly distinguishes the FDA-cleared indication (MDD) from off-label uses. This document outlines known and unknown risks, alternative treatments, and the voluntary nature of the procedure.

Comprehensive Safety Program
Clinical Collaboration: We work with psychiatric professionals for diagnosis confirmation and the management of high-risk cases.
Rigorous Screening: All patients undergo standardized screening for contraindications, such as seizure risk or implanted devices.
Treatment Protocols: We maintain written emergency procedures (including seizure and suicidality response) and provide hearing protection during all sessions.
Outcome Tracking: We utilize standardized tools (e.g., PHQ-9, GAD-7) to monitor progress and maintain thorough documentation.

Question 8

Risks and Variability

Accepted Answer

Treatment responses are individual and cannot be predicted with certainty. Some patients may not experience any benefit, and the intervention carries inherent risks. Please consult with your physician for a personalized assessment of your medical needs.

ExoMIND™ TMS Frequently Asked Questions